Iopromide (trade name is Ultravist) is on the market for more than 30 years and has been used more than 250 million times as X-ray contrast medium for patients. It is known that Iopromide may cause allergy-like reactions after being injected. With this study researchers want to find out, if the risk of severe allergy-like reactions is lower, when Iopromide will be injected into an artery, compared to the risk after an injection of Iopromid into a vein. To find this out data from four trials on Iopromide that are already completed will be combined and newly analyzed. The database used for this analysis will contain data from more than 150,000 patients.
Study Type
OBSERVATIONAL
Enrollment
133,331
Patients who have received Iopromide (iodine concentrations of 300 mg/mL or 370 mg/mL) either intra-venously or intra-arterially.
Many Locations
Multiple Locations, Germany
Number of patients with anaphylactoid reactions of Iopromide after administration
Time frame: Retrospective analysis from 31 Aug 2010 to 30 Sep 2011
Number of patients with anaphylactoid reactions after intra-arterial administration of Iopromide
Time frame: Retrospective analysis from 31 Aug 2010 to 30 Sep 2011
Number of patients with anaphylactoid reactions after intra-venous administration of Iopromide
Time frame: Retrospective analysis from 31 Aug 2010 to 30 Sep 2011
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.